Acute Myeloid Leukemia Clinical Trial
Official title:
Dose Escalation and Phase II Study of Bortezomib (IND #58443) Added to Standard Daunorubicin and Cytarabine Therapy for Patients With Previously Untreated Acute Myeloid Leukemia Age 60-75 Years
This phase II trial studies the side effects and best dose of bortezomib when given together with daunorubicin and cytarabine and to see how well it works in treating older patients with previously untreated acute myeloid leukemia. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with combination chemotherapy may kill more cancer cells.
PRIMARY OBJECTIVES:
I. To define the remission induction response rate (complete response [CR] and CR with
incomplete platelet recovery [CRp]) in older patients with previously untreated acute
myeloid leukemia treated with induction therapy comprising bortezomib in combination with
daunorubicin hydrochloride and cytarabine.
II. To define the maximum tolerated dose of bortezomib when administered in combination with
intermediate-dose cytarabine after induction therapy.
SECONDARY OBJECTIVES:
I. To describe the disease-free survival of patients treated with this regimen. II. To
describe the overall survival of patients treated with this regimen. III. To evaluate the
treatment-related toxicities in these patients.
OUTLINE: This is a multicenter, dose-escalation study of bortezomib. Doses of bortezomib are
escalated during remission consolidation therapy.
REMISSION INDUCTION THERAPY: Remission induction course 1: Patients receive bortezomib IV
over 3-5 seconds on days 1, 4, 8, and 11; daunorubicin hydrochloride IV on days 1-3; and
cytarabine IV continuously over 168 hours on days 1-7.
After completion of remission induction course 1, patients undergo bone marrow aspiration
and biopsy for evaluation of response. Patients achieving a complete response (CR) or
partial response (PR) proceed to remission consolidation therapy. Patients achieving a CR
with incomplete platelet recovery (CRp) proceed to remission consolidation therapy after
platelet counts recover. Patients with persistent leukemia (>= 20% bone marrow cellularity
and >= 5% bone marrow myeloblasts) proceed to remission induction course 2.
REMISSION INDUCTION COURSE 2: Patients receive bortezomib IV over 3-5 seconds on days 1 and
4; daunorubicin hydrochloride IV on days 1 and 2; and cytarabine IV continuously over 120
hours on days 1-5.
After completion of remission induction course 2, patients undergo bone marrow aspiration
and biopsy for evaluation of response. Patients achieving a CR or PR proceed to remission
consolidation therapy. Patients achieving a CRp proceed to remission consolidation therapy
after platelet counts recover. Patients with residual leukemia who do not meet the criteria
for PR are removed from the study.
REMISSION CONSOLIDATION THERAPY: Patients receive bortezomib IV over 3-5 seconds on days 1,
4, 8, and 11 and intermediate-dose cytarabine IV over 3 hours on days 1-5. Patients then
undergo bone marrow aspiration and biopsy for evaluation of response. Patients achieving a
CR or who demonstrate continuing CR receive a second course of remission consolidation
therapy beginning 2-4 weeks after blood counts recover.
After completion of study therapy, patients are followed every 2 months for 2 years, every 3
months for 2 years, and then annually for up to 10 years.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
| Completed |
NCT03678493 -
A Study of FMT in Patients With AML Allo HSCT in Recipients
|
Phase 2 | |
| Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
| Recruiting |
NCT05424562 -
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
|
||
| Terminated |
NCT03224819 -
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Early Phase 1 | |
| Completed |
NCT03197714 -
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
|
Phase 1 | |
| Active, not recruiting |
NCT04070768 -
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
|
Phase 1 | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Active, not recruiting |
NCT04107727 -
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
|
Phase 2 | |
| Recruiting |
NCT04385290 -
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04920500 -
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
|
N/A | |
| Recruiting |
NCT03897127 -
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
Phase 3 | |
| Active, not recruiting |
NCT04021368 -
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
|
Phase 1 | |
| Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
| Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
| Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
| Recruiting |
NCT04069208 -
IA14 Induction in Young Acute Myeloid Leukemia
|
Phase 2 | |
| Recruiting |
NCT05744739 -
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1 | |
| Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 |